Articles by Suzanne Hodsden

  1. Despite Government Incentives, Canadian Drug Makers' R&D Spending Drops 10/28/2014

    In 1987, the Canadian government cut a deal with Canadian brand name drug makers which allowed extended patent protection in return for 10 percent revenues directed towards research and development (R&D).

  2. Endo Locks Down $2.6B Deal To Acquire Auxilium 10/15/2014

    After weeks of negotiations, Endo has acquired Auxilium in a deal worth $2.6 billion, a move that adds Xiaflex, Testim, and Testopel to the company’s urology and men’s health portfolios.

  3. PhRMA Releases Two New Reports Detailing Cancer Research Progress 10/13/2014

    The Pharmaceutical Research and Manufacturers of America (PhRMA) published two reports illustrating the ways in which the oncological research sector is learning from its clinical setbacks and is forming collaborations to advance the fight against cancer.

  4. U.K. Shells Out $96M For Parkinson's, Immune System Therapies Research 10/10/2014

    The U.K.’s Medical Research Council (MRC) will invest $96M in research over the next three years as part of its Experimental Research Challenge. $9.6M has already been awarded to three projects that will set out to study Parkinson’s disease, reduced immunity in senior citizens, and specific mechanisms of addiction, pharmaphorum reports.

  5. Argos To Build $57M Bio-Manufacturing Facility In North Carolina 10/7/2014

    Argos announced its plans to invest $57 million in a new bio-manufacturing facility to house the continued development of personalized oncological immunotherapies, currently in stage 3 clinical trials, reports The News Observer.

  6. Missouri Researchers Discover Oxidative Stress-Fighting Molecule 10/6/2014

    Researchers at the University of Missouri (MU) have isolated a molecule which may effectively treat oxidative stress, a condition which is thought to be a contributing factor in as many as 200 different diseases, including cancer, Parkinson’s disease, and Alzheimer’s disease.

  7. Glialogix Receives National Multiple Sclerosis Society Funding For Treatment Development 10/1/2014

    Glialogix announced that it had signed a research agreement with the non-profit Fast Forward, a part of the National Multiple Sclerosis Society (NMSS), which would fund continued development of GLX1112, a neuroprotective oral therapy with the potential to treat progressive MS. 

  8. U.K. Researchers On Track To Develop Enzyme-Blocking Cancer, Alzheimer's “Wonder Drug” 9/30/2014

    Scientists at the Imperial College London have discovered a molecule with the potential to block the activity of an enzyme that is responsible for the progression of disease. Further investigation and development could yield a revolutionary and potent treatment for serious diseases, such as cancer, Alzheimer’s disease, and diabetes.

  9. Chinese Collaboration Yields New Treatments for Antibiotic Resistant Superbugs 9/24/2014

    A research team from A*STAR Institute of Chemical and Engineering Sciences (ICES) and the National University Hospital (NUH) in Singapore has discovered new and promising ways to enhance existing treatments in respiratory infections and antibiotic-resistant superbugs.

  10. NW Bio's Cancer Vaccine First To Receive PIM Designation In U.K.'s Early Access Scheme 9/19/2014

    Northwest Biotherapeutics (NW) announced that its new cancer immune therapy, DCVax-L, is the first drug to receive “Promising Innovative Medicine” (PIM) designation by the U.K.’s new “Early Access to Medicines Scheme” (EAMS). Like the U.S.’s compassionate use program, the EAMS aims to get urgently needed drug therapies to patients more quickly.